ClavystBio, a company established by CLA Real Estate Holdings, a wholly-owned subsidiary of Temasek, has announced its launch to accelerate the commercialisation of life sciences discoveries and innovation from Singapore.

ClavystBio will be supporting early-stage companies, starting with the emerging areas of cell and gene therapy, biomarkers and digital health. It will help companies address the lengthy and complex challenges involved in bringing novel solutions to market.

The firm has already begun delivering on its mission to accelerate life sciences innovation in Singapore by making $220 million in investment commitments to six early-stage companies and three venture partners to date. 

It is guided by a Board of Directors made up of global industry leaders with collective expertise spanning life sciences, real estate, investment, and entrepreneurship. The Board is chaired by Dr Fidah Alsagoff, Joint Head of the Enterprise Development Group (Singapore) and Head of Life Sciences, Temasek. ClavystBio is led by Chief Executive Officer, Dr Christopher Laing, who is transitioning from his role as Vice Dean, Innovation and Entrepreneurship at Duke-NUS Medical School.